College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
J Ethnopharmacol. 2021 Jun 28;274:114018. doi: 10.1016/j.jep.2021.114018. Epub 2021 Mar 11.
Dioscin and diosgenin derived from plants of the genus Dioscoreaceae such as D. nipponica and D. panthaica Prain et Burk. Were utilized as the main active ingredients of traditional herbal medicinal products for coronary heart disease in the former Soviet Union and China since 1960s. A growing number of research showed that dioscin and diosgenin have a wide range of pharmacological activities in heart diseases.
To summarize the evidence of the effectiveness of dioscin and diosgenin in cardiac diseases, and to provide a basis and reference for future research into their clinical applications and drug development in the field of cardiac disease.
Literatures in this review were searched in PubMed, ScienceDirect, Google Scholar, China National Knowledge Infrastructure (CNKI) and Web of Science. All eligible studies are analyzed and summarized in this review.
The pharmacological activities and therapeutic potentials of dioscin and diosgenin in cardiac diseases are similar, can effectively improve hypertrophic cardiomyopathy, arrhythmia, myocardial I/R injury and cardiotoxicity caused by doxorubicin. But the bioavailability of dioscin and diosgenin may be too low as a result of poor absorption and slow metabolism, which hinders their development and utilization.
Dioscin and diosgenin need further in-depth experimental research, clinical transformation and structural modification or research of new preparations before they can be expected to be developed into new therapeutic drugs in the field of cardiac disease.
薯蓣皂苷元和薯蓣皂苷来源于薯蓣科植物，如穿山龙和盾叶薯蓣，自 20 世纪 60 年代以来，一直被用作前苏联和中国治疗冠心病的传统草药的主要活性成分。越来越多的研究表明，薯蓣皂苷元和薯蓣皂苷在心脑血管疾病方面具有广泛的药理活性。
总结薯蓣皂苷元和薯蓣皂苷在心脏疾病中的有效性证据，为今后在心脏疾病领域的临床应用和药物开发研究提供依据和参考。
本综述中的文献在 PubMed、ScienceDirect、Google Scholar、中国知网（CNKI）和 Web of Science 中进行了检索。对所有符合条件的研究进行了分析和总结。
薯蓣皂苷元和薯蓣皂苷在心脏疾病中的药理活性和治疗潜力相似，能有效改善肥厚型心肌病、心律失常、心肌 I/R 损伤和阿霉素引起的心脏毒性。但由于吸收不良和代谢缓慢，薯蓣皂苷元和薯蓣皂苷的生物利用度可能过低，这阻碍了它们的开发和利用。
薯蓣皂苷元和薯蓣皂苷需要进一步深入的实验研究、临床转化和结构修饰或新制剂的研究，才能有望开发成心脏疾病领域的新型治疗药物。
